skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

Review

(3290) Views  (1055) Full article downloads

Authors: Joseph R Lutt

Published Date May 2009 Volume 2009:1 Pages 17 - 35
DOI: http://dx.doi.org/10.2147/OARRR.S4536

Joseph R Lutt

Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, Oregon, USA

Abstract: The management of rheumatoid arthritis (RA) has undergone an impressive transformation over the past few decades. Further understanding of the pathophysiology of the disease process has resulted in the development of biologic agents that target proinflammatory cytokines and both B and T lymphocytes. By blocking an important costimulatory pathway, abatacept leads to a dramatic reduction in T cell stimulation and proliferation. Multiple clinical trials have revealed consistent benefit with regards to clinical and radiographic efficacy, quality of life, and disability in patients suffering from RA who have had inadequate responses to methotrexate or tumor necrosis factor inhibitors. The possibility of remission when used early in the disease course has also been demonstrated. Importantly, abatacept has been very well tolerated with a low rate of serious infections and no apparent increase in malignancies to date. Continued surveillance of the benefits and risks will help to better define its place amongst the other biologic agents in the treatment of RA.

Keywords: abatacept, rheumatoid arthritis, infliximab, etanercept, adalimumab, rituximab, disease-modifying antirheumatic drug








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
The pathophysiology of bronchiectasis
Nitric oxide and coronary vascular endothelium adaptations in hypertension
Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study
The role of rasagiline in the treatment of Parkinson’s disease
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio